+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 3
170 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.

Age: 18Years - 75YearsAll GendersPhase 3
180 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.

Age: 18Years - 75YearsAll GendersPhase 2
119 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the combination of KarXT and KarX-EC for cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3, randomized, double-blind, placebo-controlled study aims to understand how these treatments impact cognitive function and overall condition in this patient group. Participants will be randomly assigned to receive either KarXT plus KarX-EC or a placebo, with specified doses given on specific days. The treatment period lasts 24 weeks, during which participants will be monitored closely to assess changes in cognition and daily functioning. Throughout the 24 weeks, participants will undergo evaluations including cognitive tests like the Alzheimers Disease Assessment Scale-Cognitive Subscale 11 and the Clinicians Interview-Based Impression plus Caregiver Input. Researchers will also track safety through monitoring adverse events, vital signs, lab tests, and other clinical assessments to understand the treatments impact and safety profile.

Age: 60Years - 85YearsAll GendersPhase 3
119 locations
O

Actively Recruiting

Researchers are studying the effects of anifrolumab, given as a 120 mg subcutaneous injection once weekly, for patients with systemic lupus erythematosus SLE who have not used immunosuppressants or biologic therapies before. The study aims to understand clinical outcomes like remission rates and the ability to taper off glucocorticoids GCs safely in patients not meeting low disease activity status at enrollment. Participants will receive anifrolumab injections weekly for 52 weeks, alongside their usual antimalarial treatment, with or without glucocorticoids. The study includes a 35-day screening period before treatment starts. Glucocorticoid doses may be increased during the first 4 weeks if needed, then tapered gradually between weeks 5 and 40 following a specific protocol. Those achieving remission can attempt complete withdrawal of glucocorticoids after tapering. After week 41, glucocorticoid doses will remain stable. Safety follow-up occurs 12 weeks after the last dose for participants who stop treatment after week 52. Participants will undergo regular assessments throughout the study to evaluate disease activity, remission status, glucocorticoid use, and quality of life. Researchers will monitor various outcomes, including time spent in remission, flare occurrences, skin and joint symptoms, and adverse events. The total participation time is approximately 69 weeks, including screening, treatment, and safety follow-up, with detailed tracking of glucocorticoid use and disease status at multiple time points.

Age: 18Years - 70YearsAll GendersPhase 3
107 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of a study medicine called PF-07328948 for treating adults with heart failure. This phase 2 clinical trial compares PF-07328948 to a placebo in people who are already receiving standard heart failure treatments, including sodium-glucose cotransporter 2 SGLT2 inhibitors. The study aims to determine if PF-07328948 is safe and effective for heart failure patients with specific symptoms and heart function measurements. Participants will take either PF-07328948 tablets or placebo tablets once daily by mouth for 36 weeks. There are four groups placebo, low dose, medium dose, and high dose of PF-07328948. The trial uses a randomized, double-blind design. During the study, participants will continue their regular heart failure medications alongside the study drug or placebo. Participants will be involved for about 48 weeks, including 36 weeks of treatment and follow-up. They will have 15 visits to the study clinic, with 10 visits in person and 5 conducted at home by phone. Assessments include clinical event tracking, 6-minute walk tests, and questionnaires to evaluate symptoms and physical limitations. Safety monitoring and health status questionnaires will be performed throughout the study.

Age: 18Years - 79YearsAll GendersPhase 2
150 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.

Age: 40Years - 80YearsAll GendersPhase 3
281 locations
P

Actively Recruiting

This research aims to evaluate the effects of inhaled epinephrine in individuals aged 12 years and older who experience systemic allergic reactions during allergy testing, subcutaneous immunotherapy SCIT, oral challenges, or oral immunotherapy OIT. It focuses on patients who may not be eligible for another related trial GHL-101 and seeks to better understand how inhaled epinephrine impacts these allergic events. This is a Phase 1b, open-label, multi-center exploratory study enrolling up to 100 patients. Participants receive inhaled epinephrine at doses of 0.125 mg per inhalation, with up to 8 inhalations allowed over about 6 minutes. The first dose is given quickly after identifying a Grade 2 or higher systemic allergic reaction, followed by a second dose about 10 seconds later. Inhalations continue until symptoms significantly improve or a maximum of 8 inhalations is reached, or if intramuscular epinephrine is administered. The dosing and observation happen during the participants allergy testing or immunotherapy procedures. Participants are closely observed for approximately one week during the study. Researchers monitor the time it takes for systemic symptoms to improve or completely resolve after the first dose of inhaled epinephrine. Safety assessments include vital signs and symptom evaluations. This short participation period allows researchers to gather data on inhaled epinephrines effect on allergic reactions within a controlled timeframe.

Age: 12Years +All GendersPhase 1
1 location

1-10 of 14

1